Retracted : outcome and immune reconstitution of HBV-specific immunity in patients with reactivation of occult HBV infection after alemtuzumab-containing chemotherapy regimen
UNLABELLED: Whether preemptive anti- hepatitis B virus (HBV) therapy should be considered in all hepatitis B surface antigen (HBsAg)-negative patients with occult HBV infection receiving alemtuzumab containing chemotherapy is uncertain. We determined the outcome and effect on HBV-specific immunity of an alemtuzumab-containing chemotherapy regimen in occult HBV-infected patients. Twenty-one consecutive occult HBV-infected patients treated with an alemtuzumab containing chemotherapy regimen were studied. T cell reactivity to HBV antigens and -peptides were quantified by ELISpot and the T cell subset by flow cytometry. Six of the 21 patients (28.6%) developed HBsAg seroreversion. The median (range) time to development of HBsAg seroreversion after the end of chemotherapy was 1.8 months (0.2-2.3 months). Direct sequencing showed that the occult HBV infection of all six patients (100%) was reactivated. These six patients developed severe HBV-related hepatitis. At the end of follow-up, four of these six patients (66.7%) had become negative for HBsAg again. Recovery of CD4+ T cell count and CD4+T cell reactivity against hepatitis B core antigen (HBcAg) occurred 9 months after the end of chemotherapy. Loss of HBsAg occurred after recovery of the CD4+T cell count and increased CD4+T cell reactivity against HBcAg 9 months after the end of chemotherapy.
CONCLUSION: An alemtuzumab-containing chemotherapy regimen is associated with a high risk of reactivation of occult HBV infection. Suppression of HBV immunity by an alemtuzumab-containing chemotherapy regimen would persist until 9 months after the end of chemotherapy. In occult HBV-infected patients receiving an alemtuzumab-containing chemotherapy regimen, preemptive anti-HBV therapy should be continued until 9 months after the end of chemotherapy, when recovery of HBV immunity has occurred.
| Errataetall: |
RetractionOf: Hepatology. 2008;47(6). doi: 10.1002/hep.22213 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2008 |
|---|---|
| Erschienen: |
2008 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
|---|---|
| Enthalten in: |
Hepatology (Baltimore, Md.) - 48(2008), 2 vom: 15. Aug., Seite 1-10 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hui, Chee-Kin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 05.09.2008 Date Revised 25.02.2019 published: Print RetractionOf: Hepatology. 2008;47(6). doi: 10.1002/hep.22213 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/hep.22213 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM179304887 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM179304887 | ||
| 003 | DE-627 | ||
| 005 | 20231223153546.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2008 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/hep.22213 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0598.xml |
| 035 | |a (DE-627)NLM179304887 | ||
| 035 | |a (NLM)18452145 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hui, Chee-Kin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Retracted |b outcome and immune reconstitution of HBV-specific immunity in patients with reactivation of occult HBV infection after alemtuzumab-containing chemotherapy regimen |
| 264 | 1 | |c 2008 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.09.2008 | ||
| 500 | |a Date Revised 25.02.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a RetractionOf: Hepatology. 2008;47(6). doi: 10.1002/hep.22213 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a UNLABELLED: Whether preemptive anti- hepatitis B virus (HBV) therapy should be considered in all hepatitis B surface antigen (HBsAg)-negative patients with occult HBV infection receiving alemtuzumab containing chemotherapy is uncertain. We determined the outcome and effect on HBV-specific immunity of an alemtuzumab-containing chemotherapy regimen in occult HBV-infected patients. Twenty-one consecutive occult HBV-infected patients treated with an alemtuzumab containing chemotherapy regimen were studied. T cell reactivity to HBV antigens and -peptides were quantified by ELISpot and the T cell subset by flow cytometry. Six of the 21 patients (28.6%) developed HBsAg seroreversion. The median (range) time to development of HBsAg seroreversion after the end of chemotherapy was 1.8 months (0.2-2.3 months). Direct sequencing showed that the occult HBV infection of all six patients (100%) was reactivated. These six patients developed severe HBV-related hepatitis. At the end of follow-up, four of these six patients (66.7%) had become negative for HBsAg again. Recovery of CD4+ T cell count and CD4+T cell reactivity against hepatitis B core antigen (HBcAg) occurred 9 months after the end of chemotherapy. Loss of HBsAg occurred after recovery of the CD4+T cell count and increased CD4+T cell reactivity against HBcAg 9 months after the end of chemotherapy | ||
| 520 | |a CONCLUSION: An alemtuzumab-containing chemotherapy regimen is associated with a high risk of reactivation of occult HBV infection. Suppression of HBV immunity by an alemtuzumab-containing chemotherapy regimen would persist until 9 months after the end of chemotherapy. In occult HBV-infected patients receiving an alemtuzumab-containing chemotherapy regimen, preemptive anti-HBV therapy should be continued until 9 months after the end of chemotherapy, when recovery of HBV immunity has occurred | ||
| 650 | 4 | |a Retraction of Publication | |
| 700 | 1 | |a Cheung, Winnie W |e verfasserin |4 aut | |
| 700 | 1 | |a Leung, Kar-Wai |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Vincent C C |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Bone S F |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Iris W S |e verfasserin |4 aut | |
| 700 | 1 | |a Luk, John M |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Nikki P |e verfasserin |4 aut | |
| 700 | 1 | |a Kwong, Yok-Lam |e verfasserin |4 aut | |
| 700 | 1 | |a Au, Wing-Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Yuen, Kwok-Yung |e verfasserin |4 aut | |
| 700 | 1 | |a Lau, George K |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Raymond |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hepatology (Baltimore, Md.) |d 1983 |g 48(2008), 2 vom: 15. Aug., Seite 1-10 |w (DE-627)NLM012603902 |x 1527-3350 |7 nnns |
| 773 | 1 | 8 | |g volume:48 |g year:2008 |g number:2 |g day:15 |g month:08 |g pages:1-10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/hep.22213 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 48 |j 2008 |e 2 |b 15 |c 08 |h 1-10 | ||